Transgene

Transgene Working Capital

The Working Capital of Transgene (TNG.PA) as of Nov 18, 2026 is 6.68 M EUR. In the previous year, Working Capital was 7.94 M EUR — a change of -15.84% (lower).

Working Capital

6.68 MEUR

YoY

-15.84%

Last updated:

Working Capital of Transgene is 2024 6.68 M EUR. Working Capital of Transgene was 2023 7.94 M EUR. It decreases by -15.84% lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Transgene Stock analysis

What does Transgene do? Transgene SA is a French biotechnology company specializing in the development and production of therapeutics, with a focus on cancer medications. It has a strong patent portfolio in the field of viral vectors, which are used for targeted gene therapy. The company's main areas of operation are clinical trials, research, and production. Transgene has research and production facilities in Strasbourg and Lyon, with over 100 employees. It has established partnerships with pharmaceutical companies, including Takeda Pharmaceuticals, for the development and marketing of therapeutics. Its flagship product, OncoVir-1®, is an immunomodulator that stimulates the immune system to fight tumor cells. Another promising product is TG4010, a therapeutic vaccine for non-small cell lung carcinoma. Transgene is an emerging company with a promising portfolio of cancer therapeutics, leveraging its expertise in viral vectors and collaborating closely with industry partners to expedite the development of marketable products. Transgene is expected to play a significant role in the development of new and innovative cancer treatments. Transgene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Transgene stock

Working Capital of Transgene is 6.68 M EUR in 2024.

Working Capital of Transgene changed from 7.94 M EUR to 6.68 M EUR, representing a -15.84% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Working Capital Transgene since 2006 – with annual values, charts, and detailed analysis.

Working capital is the difference between current assets and current liabilities. Positive working capital indicates a company can meet its short-term obligations.

Working Capital's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Working Capital's Transgene historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Transgene

All Key Metrics — Transgene